ADIPOR2 variant is associated with higher fasting glucose level in non-diabetic Chinese Han population

  • Na Liu
  • Guihua Yang
  • Mei Hu
  • Jing Han
  • Yuyu Cai
  • Zhiying Hu
  • Chundi Jia
  • Man ZhangEmail author
Original Article


A high but normal fasting plasma glucose level in adults is a marker for insulin resistance and future development of type 2 diabetes mellitus. We aimed to investigate whether ADIPOR2 variants are associated with increased fasting plasma glucose (FPG) in non-diabetic Chinese Han subjects who had normal FPG levels. This study included 2038 subjects among the non-diabetic Chinese Han population. The ADIPOR2 polymorphisms were genotyped by the TaqMan method. For the analysis, participants were divided into low-normal FPG group (FPG < 4.88 mmol/L) and high-normal FPG group (6.1 mmol/L > FPG ≥ 4.88 mmol/L). We identified five single nucleotide polymorphisms (SNPs) of ADIPOR2 gene: rs10773989, rs2370055, rs9300298, rs10773983, and rs13611594. There was no significant difference in FPG levels between different genotypes of rs10773989, rs2370055, rs9300298, and rs13611594. Our data showed a significant association of rs10773983 with higher FPG levels, fasting insulin levels, and homeostatic model assessment of insulin resistance (HOMA-IR) in A-allele carriers (p = 0.006, p < 0.001, and p < 0.001, respectively). The subjects in high FPG group had higher median fasting insulin level (9.25 vs 8.16 μIU/mL, p = 0.003) and higher HOMA-IR (2.21 vs 1.58, p < 0.001) than those in normal FPG group. Subjects with the A-allele of rs10773983 compared to subjects with G-allele had 1.222-fold higher risk for high-normal FPG (OR = 1.222, 95%CI = 1.010–1.478, p = 0.039). Our findings suggest that ADIPOR2 rs10773983 polymorphism may be associated with an increased risk of high-normal FPG among non-diabetic Chinese Han subjects who have normal FPG levels.


Fasting plasma glucose Single nucleotide polymorphisms Genotype Adiponectin receptor 2 



This study was funded by Beijing Municipal Administration of Hospitals’ Ascent Plan (grant number DFL20150701).

Compliance with ethical standards

The study protocol was approved by the Beijing Shijitan Hospital Ethics Committee, Capital Medical University. Written informed consent was obtained from all the participants before their enrolment in the study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Li R, Lu W, Jiang QW, Li YY, Zhao GM, Shi L, et al. Increasing prevalence of type 2 diabetes in Chinese adults in Shanghai. Diabetes Care. 2012;35(5):1028–30.CrossRefGoogle Scholar
  2. 2.
    Dagogo-Jack S, Askari H, Tykodi G. Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose. J Clin Endocrinol Metab. 2009;94(6):2031–6.CrossRefGoogle Scholar
  3. 3.
    Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. Fasting vs postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia study. Diabetes Care. 2009;32(2):281–6.CrossRefGoogle Scholar
  4. 4.
    Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.CrossRefGoogle Scholar
  5. 5.
    Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930–5.CrossRefGoogle Scholar
  6. 6.
    Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332–9.CrossRefGoogle Scholar
  7. 7.
    Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S, et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia. 2004;47(5):816–20.CrossRefGoogle Scholar
  8. 8.
    Rasmussen-Torvik LJ, Pankow JS, Jacobs DR Jr, Steinberger J, Moran A, Sinaiko AR. The association of SNPs in ADIPOQ, ADIPOR1, and ADIPOR2 with insulin sensitivity in a cohort of adolescents and their parents. Hum Genet. 2009;125(1):21–8.CrossRefGoogle Scholar
  9. 9.
    Ferguson JF, Phillips CM, Tierney AC, Pérez-Martínez P, Defoort C, Helal O, et al. Gene-nutrient interactions in the metabolic syndrome: single nucleotide polymorphisms in DIPORQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin resistance. Am J Clin Nutr. 2010;91(3):794–801.CrossRefGoogle Scholar
  10. 10.
    Stefan N, Machicao F, Staiger H, Machann J, Schick F, Tschritter O, et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia. 2005;48(11):2282–91.CrossRefGoogle Scholar
  11. 11.
    World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia.
  12. 12.
    The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–34.CrossRefGoogle Scholar
  13. 13.
    WHO . Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization; 2006. pp. 1–46. Report of a WHO/IDF Consultation Available at
  14. 14.
    Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med. 2005;353:1454–62.CrossRefGoogle Scholar
  15. 15.
    O’Malley G, Santoro N, Northrup V, D'Adamo E, Shaw M, Eldrich S, et al. High normal fasting glucose level in obese youth: a marker for insulin resistance and beta cell dysregulation. Diabetologia. 2010;53(6):1199–209.CrossRefGoogle Scholar
  16. 16.
    Shaye K, Amir T, Shlomo S, Yechezkel S. Fasting glucose levels within the high normal range predict cardiovascular outcome. Am Heart J. 2012;164(1):111–6.CrossRefGoogle Scholar
  17. 17.
    Raizes M, Elkana O, Franko M, Ravona Springer R, Segev S, Beeri MS. Higher fasting plasma glucose levels, within the normal range, are associated with decreased processing speed in high functioning young elderly. J Alzheimers Dis. 2015;49(3):589–92. Scholar
  18. 18.
    Cherbuin N, Sachdev P, Anstey KJ. Higher normal fasting plasma glucose is associated with hippocampal atrophy: the PATH study. Neurology. 2012;79(10):1019–26.CrossRefGoogle Scholar
  19. 19.
    Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes. 2008;32(Suppl 7):S13–8.CrossRefGoogle Scholar
  20. 20.
    Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332–9.CrossRefGoogle Scholar
  21. 21.
    Bermúdez VJ, Rojas E, Toledo A, Rodríguez-Molina D, Vega K, Suárez L, et al. Single-nucleotide polymorphisms in adiponectin, AdipoR1, and AdipoR2 genes: insulin resistance and type 2 diabetes mellitus candidate genes. Am J Ther. 2013;20(4):414–21.CrossRefGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2018

Authors and Affiliations

  1. 1.Clinical Laboratory Medicine, Beijing Shijitan HospitalCapital Medical UniversityBeijingChina
  2. 2.Peking University Ninth School of Clinical MedicineBeijingChina
  3. 3.Beijing Key Laboratory of Urinary Cellular Molecular DiagnosticsBeijingChina

Personalised recommendations